Villaflor V - Search Results

1

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Novak J, Salgia R, West H, Villalona-Calero MA, Sampath S, Williams T, Villaflor V, Massarelli E, Pathak R, Koczywas M, Chau B, Amini A. Novak J, et al. Among authors: villaflor v. Cancers (Basel). 2022 Aug 18;14(16):3983. doi: 10.3390/cancers14163983. Cancers (Basel). 2022. PMID: 36010982 Free PMC article. Review.

2

Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.

Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hasselle MD, et al. J Thorac Oncol. 2012 Feb;7(2):376-81. doi: 10.1097/JTO.0b013e31824166a5. J Thorac Oncol. 2012. PMID: 22198429 Free article.

3

Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.

Lukas RV, Nicholas MK, Villaflor V, Hoffman PC, Salgia R. Lukas RV, et al. Among authors: villaflor v. J Neurol Res. 2012 Feb 1;2(1):1-9. doi: 10.4021/jnr85w. J Neurol Res. 2012. PMID: 23504695 Free PMC article.

4

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Villaflor VM, Salgia R. Villaflor VM, et al. J Carcinog. 2013 Mar 18;12:7. doi: 10.4103/1477-3163.109253. Print 2013. J Carcinog. 2013. PMID: 23599689 Free PMC article.

5

Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature.

Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM. Lukas RV, et al. Among authors: villaflor vm. Dis Esophagus. 2015 Nov-Dec;28(8):772-81. doi: 10.1111/dote.12276. Epub 2014 Aug 21. Dis Esophagus. 2015. PMID: 25142531 Review.

6

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. Vigneswaran J, et al. Oncotarget. 2016 Apr 5;7(14):18876-86. doi: 10.18632/oncotarget.7739. Oncotarget. 2016. PMID: 26934441 Free PMC article.

7

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.

Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A, Salgia R. Villaflor V, et al. Oncotarget. 2016 Oct 11;7(41):66880-66891. doi: 10.18632/oncotarget.11801. Oncotarget. 2016. PMID: 27602770 Free PMC article.

8

Heuristic value-based framework for lung cancer decision-making.

Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. Mambetsariev I, et al. Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643. eCollection 2018 Jul 6. Oncotarget. 2018. PMID: 30042820 Free PMC article.

9

The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy.

Galvez C, Jacob S, Finkelman BS, Zhao J, Tegtmeyer K, Chae YK, Mohindra N, Salgia R, Jovanovic B, Behdad A, Villaflor V. Galvez C, et al. Among authors: villaflor v. Oncotarget. 2020 May 26;11(21):1953-1960. doi: 10.18632/oncotarget.27602. eCollection 2020 May 26. Oncotarget. 2020. PMID: 32523650 Free PMC article.

10

Nasopharyngeal Cancer: Is the Addition of Chemotherapy to Radiotherapy Worthwhile in an Era of Value-Based Care?

Villaflor VM, Massarelli E. Villaflor VM, et al. JCO Oncol Pract. 2020 Nov;16(11):711-712. doi: 10.1200/OP.20.00656. Epub 2020 Sep 18. JCO Oncol Pract. 2020. PMID: 32946323 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page